{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:15:07Z","timestamp":1789769707217,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 011286"],"award-info":[{"award-number":["ZIA BC 011286"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adrenocortical cancer (ACC) is a rare and aggressive cancer with dismal 5-year survival due to a lack of effective treatments. We aimed to identify a new effective combination of drugs and investigated their synergistic efficacy in ACC preclinical models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A quantitative high-throughput drug screening of 4,991 compounds was performed on two ACC cell lines, SW13 and NCI-H295R, based on antiproliferative effect and caspase-3\/7 activity. The top candidate drugs were pairwise combined to identify the most potent combinations. The synergistic efficacy of the selected inhibitors was tested on tumorigenic phenotypes, such as cell proliferation, migration, invasion, spheroid formation, and clonogenicity, with appropriate mechanistic validation by cell cycle and apoptotic assays and protein expression of the involved molecules. We tested the efficacy of the drug combination in mice with luciferase-tagged human ACC xenografts. To study the mRNA expression of target molecules in ACC and their clinical correlations, we analyzed the Gene Expression Omnibus and The Cancer Genome Atlas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We chose the maternal embryonic leucine zipper kinase (MELK) inhibitor\u00a0(OTS167) and cyclin-dependent kinase (CDK) inhibitor\u00a0(RGB-286638) because of their potent synergy from the pairwise drug combination matrices derived from the top 30 single drugs. Multiple publicly available databases demonstrated overexpression of MELK, CDK1\/2, and partnering cyclins mRNA in ACC, which were independently associated with mortality and other adverse clinical features. The drug combination demonstrated a synergistic antiproliferative effect on ACC cells. Compared to the single-agent treatment groups, the combination treatment increased G2\/M arrest, caspase-dependent apoptosis, reduced cyclins A2, B1, B2, and E2 expression, and decreased cell migration and invasion with reduced vimentin. Moreover, the combination effectively decreased Foxhead Box M1, Axin2, glycogen synthase kinase 3-beta, and \u03b2-catenin. A reduction in p-stathmin from the combination treatment destabilized microtubule assembly by tubulin depolymerization. The drug combination treatment in mice with human ACC xenografts resulted in a significantly lower tumor burden than those treated with single-agents and vehicle control groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our preclinical study revealed a novel synergistic combination of OTS167 and RGB-286638 in ACC that effectively targets multiple molecules associated with ACC aggressiveness. A phase Ib\/II clinical trial in patients with advanced ACC is therefore warranted.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02464-5","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T10:03:58Z","timestamp":1663927438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer"],"prefix":"10.1186","volume":"41","author":[{"given":"Dipranjan","family":"Laha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.C.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriem","family":"Boufraqech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelly Sampaio","family":"De Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Zeiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"11","key":"2464_CR1","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N","volume":"72","author":"MD Wooten","year":"1993","unstructured":"Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993;72(11):3145\u201355.","journal-title":"Cancer."},{"issue":"5","key":"2464_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872\u20138.","journal-title":"World J Surg"},{"issue":"11","key":"2464_CR3","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579\u201386.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2464_CR4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1\u201346.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2464_CR5","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2013-3020","volume":"98","author":"M Fassnacht","year":"2013","unstructured":"Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2464_CR6","first-page":"2817","volume":"18","author":"S Wang","year":"2017","unstructured":"Wang S, Chen SS, Gao WC, Bai L, Luo L, Zheng XG, et al. Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database. Asian Pac J Cancer Prev. 2017;18(10):2817\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"23","key":"2464_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"2464_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assie","year":"2014","unstructured":"Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607\u201312.","journal-title":"Nat Genet"},{"issue":"5","key":"2464_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016;29(5):723\u201336.","journal-title":"Cancer Cell"},{"issue":"68","key":"2464_CR10","doi-asserted-by":"publisher","first-page":"33030","DOI":"10.18632\/oncotarget.26050","volume":"9","author":"N Nilubol","year":"2018","unstructured":"Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, et al. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget. 2018;9(68):33030\u201342.","journal-title":"Oncotarget"},{"issue":"8","key":"2464_CR11","doi-asserted-by":"publisher","first-page":"e0161486","DOI":"10.1371\/journal.pone.0161486","volume":"11","author":"NJ Martinez","year":"2016","unstructured":"Martinez NJ, Rai G, Yasgar A, Lea WA, Sun H, Wang Y, et al. A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models. PLoS One. 2016;11(8):e0161486.","journal-title":"PLoS One"},{"issue":"6","key":"2464_CR12","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2464_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2464_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"2464_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jcp.24683","volume":"230","author":"M Ravi","year":"2015","unstructured":"Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FD. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16\u201326.","journal-title":"J Cell Physiol"},{"issue":"12","key":"2464_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41408-019-0249-x","volume":"9","author":"A Maes","year":"2019","unstructured":"Maes A, Maes K, Vlummens P, De Raeve H, Devin J, Szablewski V, et al. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer J. 2019;9(12):87.","journal-title":"Blood Cancer J"},{"issue":"12","key":"2464_CR17","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/leu.2013.194","volume":"27","author":"D Cirstea","year":"2013","unstructured":"Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, et al. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013;27(12):2366\u201375.","journal-title":"Leukemia"},{"issue":"3","key":"2464_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1210\/jc.2014-3182","volume":"100","author":"F Beuschlein","year":"2015","unstructured":"Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2464_CR19","doi-asserted-by":"publisher","first-page":"e01763","DOI":"10.7554\/eLife.01763","volume":"3","author":"Y Wang","year":"2014","unstructured":"Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 2014;3:e01763.","journal-title":"Elife"},{"issue":"Suppl","key":"2464_CR20","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.1016\/j.semcancer.2015.03.008","volume":"35","author":"WG Jiang","year":"2015","unstructured":"Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Suppl):S244\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2464_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12020-017-1409-z","volume":"58","author":"D Bulzico","year":"2017","unstructured":"Bulzico D, Faria PAS, Maia CB, de Paula MP, Torres DC, Ferreira GM, et al. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors? Endocrine. 2017;58(2):276\u201388.","journal-title":"Endocrine"},{"issue":"3","key":"2464_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1245\/s10434-017-6296-2","volume":"25","author":"A Aronova","year":"2018","unstructured":"Aronova A, Min IM, Crowley MJP, Panjwani SJ, Finnerty BM, Scognamiglio T, et al. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro. Ann Surg Oncol. 2018;25(3):792\u2013800.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2464_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1091\/mbc.10.1.105","volume":"10","author":"B Howell","year":"1999","unstructured":"Howell B, Larsson N, Gullberg M, Cassimeris L. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18\/stathmin. Mol Biol Cell. 1999;10(1):105\u201318.","journal-title":"Mol Biol Cell"},{"issue":"25","key":"2464_CR24","doi-asserted-by":"publisher","first-page":"22718","DOI":"10.1074\/jbc.M111605200","volume":"277","author":"P Amayed","year":"2002","unstructured":"Amayed P, Pantaloni D, Carlier MF. The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration. J Biol Chem. 2002;277(25):22718\u201324.","journal-title":"J Biol Chem"},{"issue":"Pt 21","key":"2464_CR25","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1242\/jcs.112.21.3713","volume":"112","author":"B Howell","year":"1999","unstructured":"Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18\/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci. 1999;112(Pt 21):3713\u201322.","journal-title":"J Cell Sci"},{"issue":"2","key":"2464_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00391431","volume":"113","author":"W Mueller-Klieser","year":"1987","unstructured":"Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol. 1987;113(2):101\u201322.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"51","key":"2464_CR27","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1038\/sj.onc.1210539","volume":"26","author":"S Bellanger","year":"2007","unstructured":"Bellanger S, de Gramont A, Sobczak-Thepot J. Cyclin B2 suppresses mitotic failure and DNA re-replication in human somatic cells knocked down for both cyclins B1 and B2. Oncogene. 2007;26(51):7175\u201384.","journal-title":"Oncogene"},{"issue":"10","key":"2464_CR28","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1073\/pnas.0607357104","volume":"104","author":"K Okamoto","year":"2007","unstructured":"Okamoto K, Sagata N. Mechanism for inactivation of the mitotic inhibitory kinase Wee1 at M phase. Proc Natl Acad Sci U S A. 2007;104(10):3753\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2464_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2464_CR30","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1073\/pnas.1014835108","volume":"108","author":"M Scaltriti","year":"2011","unstructured":"Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, et al. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108(9):3761\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2464_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014;74(4):1141\u201352.","journal-title":"Cancer Res"},{"issue":"7","key":"2464_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/modpathol.2013.209","volume":"27","author":"E Kuhn","year":"2014","unstructured":"Kuhn E, Bahadirli-Talbott A, Shih IM. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol. 2014;27(7):1014\u20139.","journal-title":"Mod Pathol"},{"issue":"2","key":"2464_CR33","doi-asserted-by":"publisher","first-page":"300060519897508","DOI":"10.1177\/0300060519897508","volume":"48","author":"M Li","year":"2020","unstructured":"Li M, He F, Zhang Z, Xiang Z, Hu D. CDK1 serves as a potential prognostic biomarker and target for lung cancer. J Int Med Res. 2020;48(2):300060519897508.","journal-title":"J Int Med Res"},{"issue":"4","key":"2464_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5487\/TR.2010.26.4.245","volume":"26","author":"H Son","year":"2010","unstructured":"Son H, Moon A. Epithelial-mesenchymal Transition and Cell Invasion. Toxicol Res. 2010;26(4):245\u201352.","journal-title":"Toxicol Res"},{"issue":"35","key":"2464_CR35","doi-asserted-by":"publisher","first-page":"59950","DOI":"10.18632\/oncotarget.19048","volume":"8","author":"HC Zheng","year":"2017","unstructured":"Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(35):59950\u201364.","journal-title":"Oncotarget"},{"issue":"13","key":"2464_CR36","doi-asserted-by":"publisher","first-page":"11421","DOI":"10.18632\/oncotarget.3222","volume":"6","author":"A Salomon","year":"2015","unstructured":"Salomon A, Keramidas M, Maisin C, Thomas M. Loss of beta-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition. Oncotarget. 2015;6(13):11421\u201333.","journal-title":"Oncotarget"},{"issue":"6","key":"2464_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/stem.1358","volume":"31","author":"K Joshi","year":"2013","unstructured":"Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 2013;31(6):1051\u201363.","journal-title":"Stem Cells"},{"issue":"4","key":"2464_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2011.08.016","volume":"20","author":"N Zhang","year":"2011","unstructured":"Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 2011;20(4):427\u201342.","journal-title":"Cancer Cell"},{"issue":"2","key":"2464_CR39","doi-asserted-by":"publisher","first-page":"e55743","DOI":"10.1371\/journal.pone.0055743","volume":"8","author":"S Gaujoux","year":"2013","unstructured":"Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefevre L, et al. Silencing mutated beta-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS ONE. 2013;8(2):e55743.","journal-title":"PLoS ONE"},{"issue":"1","key":"2464_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41392-020-00396-0","volume":"6","author":"J Liu","year":"2021","unstructured":"Liu J, Li J, Wang K, Liu H, Sun J, Zhao X, et al. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers. Signal Transduct Target Ther. 2021;6(1):42.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2464_CR41","first-page":"3608","volume":"38","author":"PZ Ni","year":"2017","unstructured":"Ni PZ, He JZ, Wu ZY, Ji X, Chen LQ, Xu XE, et al. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma. Oncol Rep. 2017;38(6):3608\u201318.","journal-title":"Oncol Rep"},{"issue":"2","key":"2464_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jcb.20187","volume":"93","author":"CI Rubin","year":"2004","unstructured":"Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem. 2004;93(2):242\u201350.","journal-title":"J Cell Biochem"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02464-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02464-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02464-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T10:09:49Z","timestamp":1663927789000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02464-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2464"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02464-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human adrenocortical tissue samples were collected under a protocol designed to evaluate the molecular biology of endocrine neoplasms (clinicaltrials.gov<i>,<\/i> NCT01005654), which was approved by the Institutional Review Board, National Cancer Institute (NCI), National Institutes of Health (NIH), and the NIH Office of Human Subject Research. All participants provided written informed consent.All animal experiments were approved by the National Institutes of Health, Bethesda, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors provide consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}